HARROW, INC. (HROW) Q3 2025 10-Q Quarterly Report
HARROW, INC. (HROW) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
HARROW, INC. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: U.S. government shutdown starting Oct 1, 2025 causing FDA, CMS, SEC staffing cuts, delaying product approvals, reimbursement, and capital access
- • Updated legal risk: Ongoing FDA inspections and warning letters (latest May 2023, 2024), with voluntary recalls and remediation raising compliance scrutiny
- • Regulatory risk: Inflation Reduction Act enabling Medicare drug price setting, penalties for price increases above inflation, increasing pricing pressure risks
- • Operational risk: ImprimisRx facility licensing issues in California risking reduced sales, with potential material impact if other states impose similar restrictions
- • Financial risk: Possible supply chain tariffs up to 150% on APIs and components could raise input costs, disrupt supply, and compress gross margins
Get deeper insights on HARROW, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.